SEC Form 4 · accession 0001513162-18-000125
Anixa Biosciences Inc · ANIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Amit Kumar
Officer — Chief Executive Officer · Director
Period of report
May 8, 2018
Accepted (ET)
May 14, 2018 · 8:44 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000715446
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock AwardF1 | $0.00 | May 8, 2018 | A | 1,500,000 | A | — | May 8, 2028 | Common Stock | 1,500,000 | 1,500,000 | D |
| Employee Stock OptionF2 | $3.70 | May 8, 2018 | A | 600,000 | A | — | May 8, 2028 | Common Stock | 600,000 | 600,000 | D |
| Employee Stock OptionF3 | $3.70 | May 8, 2018 | A | 1,500,000 | A | — | May 8, 2028 | Common Stock | 1,500,000 | 1,500,000 | D |
Explanation of responses
- F1The restricted stock award vests in its entirety if during any 20 trading day period on or before May 31, 2021 in which the reporting person is employed by the issuer, the average closing stock price of the issuers common stock is at least $11.00.
- F2The option vests and becomes exercisable in equal installments on a monthly basis over three years beginning on May 31, 2018.
- F3The option vests and becomes exercisable as follows: (i) 500,000 shares vest if during any 20 trading day period on or before May 31, 2021, the average closing stock price of the issuers common stock is at least $5.00, (ii) 500,000 shares vest if during any 20 trading day period on or before May 31, 2021, the average closing stock price of the issuers common stock is at least $7.00, and (iii) 500,000 shares vest if during any 20 trading day period on or before May 31, 2021, the average closing stock price of the issuers common stock is at least $8.00